Canlitinib

Modify Date: 2024-04-08 02:22:34

Use of Canlitinib

Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study.

Name	Canlitinib

Description	Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Met/HGFR
References	[1]. Zhang, Zhiqiang, et al. Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof. WO2017-CN104518

Molecular Formula	C₃₃H₃₁F₂N₃O₇
Molecular Weight	619.61